anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Participants aged 16-65 years old were enrolled. Hepatitis E vaccine, containing 30mcg of HEV239 recombinant antigen adsorbed to alum adjuvant suspended in 0.5ml phosphate buffer, was given at 0, 1, 6m for three doses.
Pleasure and pain are two fundamental, intertwined aspects of human emotions. Pleasurable sensations can reduce subjective feelings of pain and vice versa, and we often perceive the termination of pain as pleasant and the absence of pleasure as unpleasant. This implies the existence of brain systems that integrate them into modality-general representations of affective experiences. Here, we examined representations of affective valence and intensity in an functional MRI (fMRI) study (n = 58) of sustained pleasure and pain. We found that the distinct subpopulations of voxels within the ventromedial and lateral prefrontal cortices, the orbitofrontal cortex, the anterior insula, and the amygdala were involved in decoding affective valence versus intensity. Affective valence and intensity predictive models showed significant decoding performance in an independent test dataset (n = 62). These models were differentially connected to distinct large-scale brain networks-the intensity model to the ventral attention network and the valence model to the limbic and default mode networks. Overall, this study identified the brain representations of affective valence and intensity across pleasure and pain, promoting a systems-level understanding of human affective experiences.
An immunosuppressive peptide of 40 kDa molecular weight, isolated from the submandibular glands (SMG*) of rats, had the capacity to suppress immune reactions upon parenteral administration to rats and mice. The peptide was identified as glandular kallikrein (K1) by partial sequencing and by enzymatic activity. Further experiments revealed that the excision of SMG (SMGx) from Lewis rats prevents the oral induction of immunological tolerance against native bovine type II collagen (BCII). Thus SMGx rats, when they were given oral BCII and were subsequently immunized with the same antigen, developed collagen induced arthritis (CA), while normal rats given an identical treatment were protected from the disease. When SMGx rats were orally given porcine K1 in conjunction with BCII, the capacity of such animals to develop oral tolerance was fully restored. These results indicate that normal SMG function is required for the induction of oral tolerance and that K1 is involved in mediating this function.
Bladder cancer is the fourth most common cancer in the United States with over 60,000 new cases each year. It can usually be treated initially by insertion of an endoscope into the bladder and surgically removing the tumor, a procedure known as cystoscopy and trans-urethral resection of bladder tumor (TURBT). For most patients this procedure will successfully remove all of the detectable tumor. Unfortunately over 40% of all patients will develop a cancer recurrence in less than two years and all patients remain at increased risk of recurrence for the remainder of their lives. This risk requires life long monitoring and this is best accomplished with regular cystoscopic examinations. The goal of this study is to test whether the drug valproic acid can cause changes in bladder tumors that might inhibit their growth. Patients with suspected bladder cancer will be invited to participate in the study, if a tumor is observed during cystoscopy it will be sampled for research purposes and then according to standards of care, the patient scheduled for TURBT under general anesthesia. In the interval between discovery of a bladder tumor and resection, usually two to four weeks, the patient will be given valproic acid to take orally. In addition, tumors from patients with known or suspected bladder cancer referred for TURBT or cystectomy will be sampled. The tumor pieces obtained before and after taking valproic acid and from the referral patients not treated with valproic acid will be analyzed to see if the drug has changed what genes are active. We have found that valproic acid causes bladder cancer cells to make more of the protein, thrombospondin-1. This protein inhibits the growth of new blood vessels and so increased thrombospondin-1 in bladder tumors should inhibit their growth by decreasing the blood supply. Valproic acid may change thrombospondin-1 levels through inhibition of histone deacetylases. We will also assay HDAC activity in the tumor specimens. If valproic acid alters thrombospondin-1 levels and HDAC activity in bladder cancer patients further study to see if it can reduce growth will be justified. Valproic acid is a drug approved for the treatment of seizure disorders that is generally well tolerated with few side effects. It may prove useful in reducing bladder cancer recurrence and progression.
The invention discloses a traditional Chinese medicine pill for curing radiculitis and a preparation method thereof. The traditional Chinese medicine pill is mainly prepared from the following raw materials: Rubus lambertianus Ser. root, cajeput, Ampelopsis Cantoniensis (Hook. et Arn.) planch root, malva verticillata root, solanum indicum, white beans, siphon, hypecoum leptocarpum, glechoma longituba, bee venom, lens, euonymus bungeanus, urena lobata, urena procumbens, cissus repens, Schefflera leucantha R. Vig., cantonese speranskia, Kadsura heteroclita (Roxb.) Craib, Neohymenopogon parasiticus (Wall.) S. S. R. Bennet, pedicularis chenocephala, silverweed cinquefoil root, ardisia villosa, blumea balsamifera, fmoes officinalis ames, white yam rhizome and plumbago zeylanica. The traditional Chinese medicine pill for curing radiculitis is precise in formula, reasonable in matching, long in medicine effect duration, remarkable in curative effect, short in treatment course, quick in result, free of side effect, and convenient to use.
Glaucoma is the leading cause of irreversible blindness worldwide. Often asymptomatic for years, this disease can progress significantly before patients become aware of the loss of visual function. Critical examination of the optic nerve through ophthalmoscopy or using fundus images is a crucial component of glaucoma detection before the onset of vision loss. The vertical cup-to-disc ratio (VCDR) is a key structural indicator for glaucoma, as thinning of the superior and inferior neuroretinal rim is a hallmark of the disease. However, manual assessment of fundus images is both time-consuming and subject to variability based on clinician expertise and interpretation. In this study, we develop a robust and accurate automated system employing deep learning (DL) techniques, specifically the YOLOv7 architecture, for the detection of optic disc and optic cup in fundus images and the subsequent calculation of VCDR. We also address the often-overlooked issue of adapting a DL model, initially trained on a specific population (e.g., European), for VCDR estimation in a different population. Our model was initially trained on ten publicly available datasets and subsequently fine-tuned on the REFUGE dataset, which comprises images collected from Chinese patients. The DL-derived VCDR displayed exceptional accuracy, achieving a Pearson correlation coefficient of 0.91 (P = 4.12 × 10-412) and a mean absolute error (MAE) of 0.0347 when compared to assessments by human experts. Our models also surpassed existing approaches on the REFUGE dataset, demonstrating higher Dice similarity coefficients and lower MAEs. Moreover, we developed an optimization approach capable of calibrating DL results for new populations. Our novel approaches for detecting optic discs and optic cups and calculating VCDR, offers clinicians a promising tool that significantly reduces manual workload in image assessment while improving both speed and accuracy. Most importantly, this automated method effectively differentiates between glaucoma and non-glaucoma cases, making it a valuable asset for glaucoma detection.
HER2 amplification-associated molecular alterations and clinicopathologic features in colorectal cancers (CRCs) have not been well established. In this study, we assessed the prevalence of HER2 amplification and microsatellite instability (MSI) status of 992 patients with primary CRC. In addition, molecular alterations of HER2 amplified and unamplified CRCs were examined and compared by next-generation sequencing. HER2 amplifications were found in 41 (4.1%) of 992 primary CRCs. HER2 amplification was identified in 1.0% of the right colonic tumors, 5.1% of the left colonic tumors, and 4.8% of the rectal tumors. Approximately 95% of HER2 amplification was observed in the left colon and rectum. Seven (87.5%) of eight metastatic tumors showed HER2 amplification. Most clinicopathologic features were unrelated to HER2 amplification except tumor size and MSI status. All 41 HER2 amplified CRCs were microsatellite stable. In a molecular analysis of frequently identified somatic mutations in CRCs, HER2 amplified CRCs showed a lower rate of KRAS mutations (24.4%) but a higher rate of TP53 mutations (83%) than unamplified CRCs. No BRAF and NRAS mutations were identified in HER2 amplified CRCs. Our study suggests that HER2 amplified CRCs are mutually exclusive of MSI and harbor less frequent KRAS/NRAS/BRAF mutations but frequent T53 mutations.
Dental implant made by immersing a root made of inert material in a culture of undifferentiated mesenchymal cells (22), is new. The medium (21) available to the cells contains specific growth cultures which allow the cells to differentiate into cementoblasts or fibroblasts.  An Independent claim also included for a device where cells can be grown on the implant. Cells and culture medium are held in a culture container separated by a porous wall (20). The root is agitated side to side or rotated every 1 to 60 seconds by 0.005 to 2 mm, stimulating cell growth on the root. This is done mechanically, hydraulically or magnetically.
Relating to cyclotriphosphazene and its fluorescent nano-microsphere as well as a preparation method, the invention provides hexaminoacid ester phenoxyl cyclotriphosphazene, its fluorescent nano-microsphere and a preparation method thereof. Hexaminoacid ester phenoxyl cyclotriphosphazene has a general structural formula as shown in the picture, wherein, M is amino acid x ester. And hexaminoacid ester phenoxyl cyclotriphosphazene is prepared by first reacting 6 pairs of carboxyphenoxyl cyclotriphosphazene with thionyl chloride, and then adding amino-acid ester hydrochloride and an acid binding agent for reaction. Composed of hexaminoacid ester phenoxyl cyclotriphosphazene, the fluorescent nano-microsphere is prepared by the steps of: dissolving hexaminoacid ester phenoxyl cyclotriphosphazene in an organic solvent, then adding distilled water dropwisely, and pouring water, then conducting dialysis and freeze-drying, thus obtaining the fluorescent nano-microsphere. Hexaminoacid ester phenoxyl cyclotriphosphazene has stable structure, good biocompatibility, easy degradation, degradation product free of toxicity and inflammatory response, and its preparation method has a yield up to over 80%, mild reaction conditions, and a simple process, thus boasting very good industrial application prospects. Under ultraviolet excitation, the fluorescent nano-microsphere can generate a fluorescence phenomenon, and can serve as a carrier of targeting drug delivery.
The present disclosure relates generally to systems and methods for providing intelligent control to an imaging system, an associated patient machine, or both. In one embodiment, the system and method provide automated Magnetic Resonance Imaging (MRI) control. An MRI infusion pump/patient monitor may have a cloud/internet connection and may transmit patient data to a patient network while a patient is being MRI. The data may be compared to a historical patient database in the patient network. The pump algorithm may be selected based on a number of factors. Such factors can include patient life and electronic medical records. The selected pump algorithm may be used to control an MRI infusion pump.
Co-occurrence of chronic pain and clinically significant symptoms of anxiety and/or depression is regularly noted in the literature. Yet, little is known empirically about population prevalence of co-occurring symptoms, nor whether people with co-occurring symptoms constitute a distinct subpopulation within US adults living with chronic pain or US adults living with anxiety and/or depression symptoms (A/D). To address this gap, this study analyzes data from the 2019 National Health Interview Survey, a representative annual survey of self-reported health status and treatment use in the United States (n = 31,997). Approximately 12 million US adults, or 4.9% of the adult population, have co-occurring chronic pain and A/D symptoms. Unremitted A/D symptoms co-occurred in 23.9% of US adults with chronic pain, compared with an A/D prevalence of 4.9% among those without chronic pain. Conversely, chronic pain co-occurred in the majority (55.6%) of US adults with unremitted A/D symptoms, compared with a chronic pain prevalence of 17.1% among those without A/D symptoms. The likelihood of experiencing functional limitations in daily life was highest among those experiencing co-occurring symptoms, compared with those experiencing chronic pain alone or A/D symptoms alone. Among those with co-occurring symptoms, 69.4% reported that work was limited due to a health problem, 43.7% reported difficulty doing errands alone, and 55.7% reported difficulty participating in social activities. These data point to the need for targeted investment in improving functional outcomes for the nearly 1 in 20 US adults living with co-occurring chronic pain and clinically significant A/D symptoms.
Arm B: Capecitabine 1,000 mg/m2, orally, twice daily for 14 days followed by a 7 day rest (14-7) (3-week cycle length ). The control arm dose of capecitabine has been reduced from the US Food and Drug Administration approved dose of 1,250 mg/m2, orally, twice daily due to common clinical practice.
INTRODUCTION: Acute kidney injury (AKI) is a common complication after on-pump cardiac surgery, and previous studies have suggested that blood glucose is associated with postoperative AKI. However, limited evidence is available regarding intraoperative glycemic thresholds in cardiac surgery. The aim of this study was to explore the association between peak intraoperative blood glucose and postoperative AKI, and determine the cut-off values for intraoperative glucose concentration associated with an increased risk of AKI.
METHODS: The study was retrospective and single-centered. Adult patients in West China Hospital of Sichuan University who underwent on-pump cardiac surgery (n = 3375) were included. The primary outcome was the incidence of AKI. Multivariable logistic analysis using restricted cubic spline was performed to explore the association between intraoperative blood glucose and postoperative AKI.
RESULTS: The incidence of AKI in the study population was 18.0% (607 of 3375). Patients who developed AKI had a significantly higher peak intraoperative glucose during the surgery compared to those without AKI. After adjustment for confounders, the incidence of AKI increased with peak intraoperative blood glucose (adjusted odds ratio, 1.08, 95% confidence interval 1.03, 1.12). Furthermore, it was demonstrated that the possibility of AKI was relatively flat till 127.8 mg/dL (7.1 mmol/L) glucose levels which started to rapidly increase afterward.
CONCLUSIONS: Increased intraoperative blood glucose was associated with an increased risk of AKI. Among patients undergoing on-pump cardiac surgery, avoiding a high glucose peak (i.e., below 127.8 mg/dL [7.1 mmol/L]) may reduce the risk of postoperative AKI.
PURPOSE:To obtain a medicinal preparation for external use, resistant to the aging, degradation and discoloration of the substrate and the lowering of the adhesivity, by adding zeolite to a substrate. CONSTITUTION:The objective medicinal preparation for external application is obtained by adding 0.1-30wt% zeolite to a substrate. It can be applied to an agent for external use such as sticking plaster, plaster, etc. containing a non-aqueous adhesive substance as a substrate, an agent for external use such as poultice containing a water-containing gel as a substrate, or an agent for external use containing a substrate having emulsified form such as ointment, cream, etc. Various problems caused by metals, e.g. aging, degradation or discoloration of substrate, loss of adhesivity, etc., can be prevented by the addition of zeolite, and the deactivation, decomposition, discoloration or color development of an anionic medicinal drug caused by chelation can also be prevented. Furthermore, the function of zeolite to retain the active component enables the slow-releasing of the active component, the elongation of the pharmacological effect and the prevention of dissipation of the active component.
A system includes a medical device and a charging device. A sterile barrier may be interposed between the medical device and the charging device. The medical device includes an integral power source and an active element. The charging device is configured to charge the integral power source. The charging device may charge the integral power source through direct contact between features of the charging device and features the medical device. The charging device may alternatively charge the integral power source wirelessly, such as through inductive coupling. The medical device may include conductive prongs that are retained by the charging device. The charging device may physically couple with the medical device via magnets. The medical device and the charging device may be provided together in a sterile package as a kit. The kit may also include a reclamation bag to facilitate reclamation of electrical components.
Wet-sheet packaging eliminates troubles a user encounters in spreading out a wet sheet after the wet sheet is taken out of the packaging, thereby improving convenience in using the wet sheet. A layered body of folded wet sheets is accommodated in an inner container inside an outer bag that is provided with an outer take-out opening at its surface. The outer take-out opening is freely opened and closed by a closure sheet. The layered body allows a user to grasp an edge of the upper surface of the topmost wet sheet and to spread out the wet sheet. The layered body is made by stacking multiple wet sheets, each of which is folded into a zigzag shape, forming a band-shaped folded body. The edge is disposed at the middle part of the folded body in the width direction facing the lengthwise direction.
BACKGROUND: Solid tumors such as glioblastoma (GBM) exhibit hypoxic zones that are associated with poor prognosis and immunosuppression through multiple cell intrinsic mechanisms. However, release of extracellular vesicles (EVs) has the potential to transmit molecular cargos between cells. If hypoxic cancer cells use EVs to suppress functions of macrophages under adequate oxygenation, this could be an important underlying mechanism contributing to the immunosuppressive and immunologically cold tumor microenvironment of tumors such as GBM.
METHODS: EVs were isolated by differential ultracentrifugation from GBM cell culture supernatant. EVs were thoroughly characterized by transmission and cryo-electron microscopy, nanoparticle tracking analysis (NTA), and EV marker expression by Western blot and fluorescent NTA. EV uptake by macrophage cells was observed using confocal microscopy. The transfer of miR-25/93 as an EV cargo to macrophages was confirmed by miRNA real-time qPCR. The impact of miR-25/93 on the polarization of recipient macrophages was shown by transcriptional analysis, cytokine secretion and functional assays using co-cultured T cells.
RESULTS: We show that indirect effects of hypoxia can have immunosuppressive consequences through an EV and microRNA dependent mechanism active in both murine and human tumor and immune cells. Hypoxia enhanced EV release from GBM cells and upregulated expression of miR-25/93 both in cells and in EV cargos. Hypoxic GBM-derived EVs were taken up by macrophages and the miR-25/93 cargo was transferred, leading to impaired cGAS-STING pathway activation revealed by reduced type I IFN expression and secretion by macrophages. The EV-treated macrophages downregulated expression of M1 polarization-associated genes Cxcl9, Cxcl10 and Il12b, and had reduced capacity to attract activated T cells and to reactivate them to release IFN-γ, key components of an efficacious anti-tumor immune response.
CONCLUSIONS: Our findings suggest a mechanism by which immunosuppressive consequences of hypoxia mediated via miRNA-25/93 can be exported from hypoxic GBM cells to normoxic macrophages via EVs, thereby contributing to more widespread T-cell mediated immunosuppression in the tumor microenvironment.
Sublingual gland herniation into the submandibular space through a mylohyoid muscle defect is a common anatomical variation; however, salivary gland cancers that arise from a herniated sublingual gland have not been described yet. Here, we report three patients with salivary gland cancers originating from a herniated sublingual gland. All tumors were detected as palpable submandibular masses, located anterior to the submandibular gland, medial to the mandible, and lateral to the mylohyoid muscle, with contact with the sublingual gland through a mylohyoid muscle defect. Intraoperative findings confirmed that the masses were derived from herniated sublingual glands. Pathological examination showed one case of mucoepidermoid carcinoma and two cases of adenoid cystic carcinoma. Imaging findings of the tumor location, in addition to the continuity with the sublingual gland through the mylohyoid muscle defect, are crucial for accurately diagnosing the tumor origin, which is essential for determining the appropriate clinical management.
Mammary fibrosis in dairy cows is a chronic condition caused by mastitis, and can lead to serious culling of dairy cows resulting in huge economic losses in the dairy industry. MicroRNAs (miRNAs) exert an important role in regulating mammary gland health in dairy cows. This study investigated whether exosomal miRNAs in mammary epithelial cells can regulate the proliferation of bovine mammary fibroblasts (BMFBs) in mastitis. Liposome transfection technology was used to construct a cellular model of the overexpression and inhibition of miRNAs. The STarMir software, dual luciferase reporter gene test, real-time quantitative PCR (qRT-PCR), a Cell Counting Kit-8 (CCK-8), and a Western Blot and plate clone formation test were used to investigate the mechanism by which bta-miR-1296 regulates the proliferation of BMFBs. Target gene prediction results revealed that glutamate-ammonia ligase was a direct target gene by which bta-miR-1296 regulates cell proliferation. It was found that bta-miR-1296 significantly inhibited the proliferation of BMFBs. After BMFBs were transfected with a bta-miR-1296 mimic, mRNA expression in the extracellular matrix (ECM), α-smooth muscle actin (α-SMA), collagen type I alpha 1 chain (COL1α1) and collagen type III alpha 1 chain (COL3α1), and various cell growth factors (basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF), platelet-derived growth factor-BB (PDGF-BB), and transforming growth factor-β1 (TGF-β1)) were down-regulated, and the expressions of α-SMA, COL1α1, COL3α1, phospho-extracellular regulated protein kinases, phospho-protein kinase B, TGF-β1, and phospho-Smad family member3 proteins were inhibited. In conclusion, bta-miR-1296 can inhibit the proliferation of BMFBs and the synthesis of ECM in BMFBs, thus affecting the occurrence and development of mammary fibrosis in dairy cows and laying the foundation for further studies to clarify the regulatory mechanism of mammary fibrosis.